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Individual microRNAs (miRNAs) are rapidly down-regulated during
conditions of cellular activation and infection, but factors mediat-
ing miRNA turnover are poorly understood. Infection of mouse
cells with murine cytomegalovirus (MCMV) induces the rapid
down-regulation of an antiviral cellular miRNA, miR-27. Here, we
identify a transcript produced by MCMV that binds to miR-27 and
mediates its degradation. UV-crosslinking and high-throughput
sequencing [CRAC (UV-crosslinking and analysis of cDNA)] identi-
ﬁed MCMV RNA segments associated with the miRNA-binding pro-
tein Argonaute 2 (Ago2). A cluster of hits mapped to a predicted
miR-27-binding site in the 3′UTR of the previously uncharacterized
ORF, m169. The expression kinetics of the m169 transcript corre-
lated with degradation of miR-27 during infection, and m169 ex-
pression inhibited miR-27 functional activity in a reporter assay.
siRNA knockdown of m169 demonstrated its requirement for miR-
27 degradation following infection and did not affect other host
miRNAs. Substitution of the miR-27-binding site in m169 to create
complementarity to a different cellular miRNA, miR-24, resulted in
down-regulation of only miR-24 following infection. The m169
transcript is cytoplasmic, capped, polyadenylated, and interacts
with miRNA-27 through seed pairing: characteristic features of the
normal messenger RNA (mRNA) targets of miRNAs. This virus–host
interaction reveals a mode of miRNA regulation in which a mRNA
directs the degradation of a miRNA. We speculate that RNA-medi-
ated miRNA degradation could be a more general viral strategy for
manipulating host cells.
herpesvirus | RNA crosslinking | RNA degradation | RNA turnover
Viruses devote a large portion of their genomes to strategiesfor manipulating host cells and evading antiviral defense
mechanisms. Numerous host miRNA-binding sites have been
predicted in different viral genomes, but the validity and func-
tional relevance of most predictions remain unclear. The best
studied miRNA–virus interactions demonstrate that RNA viruses
can use cellular miRNAs to regulate their life cycles; for example,
the interaction between hepatitis C virus and miR-122 enhances
viral replication (1), whereas the interaction between HIV-1 and
miR-29 mediates its localization to P bodies (2). Direct inter-
actions between host miRNAs and viral genes can also suppress
viral gene expression and replication (3–6) (reviewed in Ref. 7).
However, the factors driving the evolution of these interactions
remain somewhat controversial, because they may relate to viral
mechanisms for persistence and latency rather than host defense
(8, 9). At the same time, the expression levels of speciﬁc miRNAs
can indirectly inﬂuence infections; miRNAs are key components
of the innate immune response (10, 11) and exert antiviral
properties by modulating host cofactors and pathways required by
viruses (12–15). We previously showed that miR-27 limits the
replication capacity of murine cytomegalovirus (MCMV) but is
rapidly degraded during the lytic infection (16). Actinomycin D
treatment upon infection prevents miR-27 down-regulation,
suggesting that an RNA produced during infection might be
involved (16). A small nuclear RNA (snRNA) in Herpesvirus
saimiri (HVS), HSUR-1, was recently shown to bind to miR-27
and mediate its degradation (17). However, no homolog of
HSUR-1 has been identiﬁed in other viral families. miRNA
turnover mechanisms in animals remain poorly characterized
(18). The aim of this work was to identify miR-27 interaction sites
in the MCMV transcriptome and determine whether any of these
could mediate miR-27 turnover. To achieve this aim, we imple-
mented a UV-crosslinking method that precisely mapped a miR-
27-binding site to the previously uncharacterized viral transcript,
m169. Our ﬁndings demonstrate that, despite hundreds of pre-
dicted miR-27-binding sites, one sequence is responsible for the
degradation of miR-27 upon infection.
Results
High-Throughput Identiﬁcation of MCMV RNAs Associated with
Mouse Argonaute 2. The probability of ﬁnding potential miRNA-
binding sites at random is high in the large (230-kb) MCMV ge-
nome. At least 134 potential miR-27–binding sites are predicted
using criteria of seed pairing and a minimal free energy cutoff of
−20 kcal/mol (Fig. S1). We, therefore, attempted to experimen-
tally identify binding sites for miR-27 on the MCMV tran-
scriptome. miRNAs function within the RNA-induced silencing
complex (RISC), the effectors of which are Argonaute (Ago)
proteins. We adapted the UV-crosslinking and analysis of cDNA
(CRAC) technique (19) to identify RNA sequences bound to the
Ago2 protein. Living cells expressing tagged Ago2 were UV-ir-
radiated at 254 nm, and RNA was puriﬁed and reverse tran-
scribed, and the cDNAs were sequenced on a Solexa GAII. The
approach is similar to previous HITS-CLIP (high-throughput
sequencing of RNA isolated by crosslinking immunoprecipita-
tion) analyses (20), but the Ago2 protein was N-terminally tagged
with protein A and His6 (PTH-Ago2) to enable puriﬁcation under
highly denaturing conditions (Fig. 1 and SI Materials and Meth-
ods). Transfection with the PTH-Ago2 construct resulted in
modest over-expression (1.4-fold) of the tagged protein com-
pared with endogenous Ago2 in NIH 3T3 cells under conditions
where > 70–80% of cells are transfected (Fig. S2). Transfection
with PTH-Ago2 did not interfere with the viral infection, as
assessed by comparing immediate early viral gene expression
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(ie1) and viral growth kinetics in untransfected and transfected
cells (Fig. S2). For the purpose of this study, cells were mock-
infected or infected with MCMV at 20 h posttransfection at
a multiplicity of infection (MOI) of 5. Analyses were performed 8
h postinfection; under these infection conditions, approximately
half of miR-27 is degraded (Fig. S3), indicating that the putative
inhibitor is likely to be associated with the RISC at this time point.
Cells were crosslinked and lysed, and the RNA–protein com-
plexes were puriﬁed as described (19), with modiﬁcations de-
tailed in SI Materials and Methods. RNA classes identiﬁed in
uninfected and infected cells are indicated in Table S1. In this
study, we focus exclusively on reads mapped to the viral genome
(∼1% of total reads; Table S1). Almost all regions with high hit
density represented annotated viral miRNAs; clusters of reads
from 15 of the 18 previously reported pre-miRNAs (21, 22) are
recovered at this early time point (Table S2). The clusters with
the highest hit density mapped to miRNAs in the m01 and M23
clusters (Fig. 2 and Table 1). The data shown in Fig. 2 are based
on one sample, but the rankings of viral hit densities were
comparable in another sample prepared from infected cells at
the same time point, where miR-27 was overexpressed by
transfection of a synthetic mimic (Table S3).
m169 RNA Is a 1,669-nt mRNA with a miR-27-Binding Site in Its 3′UTR
That Cross-Links to Argonaute 2. The cluster with the ﬁfth highest
peak hit density mapped to positions 228,044–228,068 in the (−)
strand of the viral genome and included a predicted miR-27-
binding site with complementarity to nucleotides 1–7 and 16–21
in the miRNA (Fig. 3). In CRAC and related techniques, an
increased rate of microdeletions is seen in the sequence data at
the site of protein crosslinking (19, 23–26). This is attributable to
errors introduced by reverse transcriptase when bypassing the
crosslinked site and can be used to pinpoint the precise protein-
binding site. Strikingly, the highest incidence of deletions local-
ized to the region complementary to miR-27 (Fig. 3). This miR-
27-binding site is 231 nt downstream of the m169 ORF, which
has predicted TATA-binding elements and a polyadenylation
signal as indicated in Fig. 4A. Using 5′ RACE (27), we identiﬁed
a transcript produced from this locus with a transcriptional start
site at position 229,097 (including a nontemplated G at the 5′
end, consistent with the presence of a cap), and this was validated
by primer extension (Fig. 4B). The 3′ end of the transcript was
identiﬁed based on reverse transcription with an oligo(dT) adapter
primer followed by PCR and sequencing, as described in Ref. 28.
This procedure conﬁrmed the presence of a poly(A) tail and
mapped the 3′ end to position 227,429, which is 23 nt downstream
of the predicted polyadenylation signal (Fig. 4). Northern blot
analysis with a probe spanning the miR-27-binding site conﬁrmed
that a ∼1.7-kb RNA is produced from this locus, and no smaller
processing products were observed (Fig. 4B). The expression
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Fig. 1. Ago2-CRAC method in MCMV-infected NIH 3T3 cells. (A) Schematic
of PTH-Ago2 construct. (B) Left, Western blot showing expression of PTH-
Ago2 in uninfected and infected cells at 8 h postinfection, detected using an
anti-PAP antibody recognizing the protein A tag. (B) Right, nitrocellulose
membrane showing 32P-labeled RNA crosslinked to mouse PTH-Ago2 fol-
lowing immunoprecipitation and resolution on a 4–12% Bis-Tris NuPage gel.
The excised fragment used for further steps in the CRAC protocol is brack-
eted and protein size markers indicated.
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Fig. 2. Location of Ago2-binding sites in the MCMV transcriptome. Distribution of Solexa reads (blue) on the (+) and (−) strands of the MCMV genome, in
comparisonwith location of annotated viralmiRNAs (red). Dashed boxes showa zoomed in viewof two regions of the genomewith highhit density clusters (Table
1): the m01 miRNAs (left) and a region of the genome downstream of the annotated ORF, m169 (right). The predicted binding site for miR-27 is shown in green.
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kinetics of the m169 RNA were closely correlated with the deg-
radation of miR-27 upon infection (Fig. 4C). As expected, treat-
ment of cells with actinomycin D blocked m169 RNA expression
(Fig. 4C) and rescued miR-27 down-regulation upon infection.
Absolute quantitative (q)RT-PCR analysis of miR-27 and m169
levels in infected cells in comparison with synthetic miR-27 and
in vitro-transcribed m169 standards demonstrated that similar
amounts of each RNA are expressed between 12–24 h post-
infection (Fig. 4D). We conclude that MCMV generates a 1,669-
nt transcript that is produced during the lytic infection and con-
tains a miR-27-binding site in its 3′UTR that precisely matches
a site of Ago2 association.
MCMV m169 RNA Blocks miR-27 Functional Activity and Mediates
miR-27 Degradation. To examine the effect of m169 RNA on the
functional activity of miR-27, we constructed a miR-27 sensor
containing three miR-27-binding sites behind the 3′UTR of
Renilla luciferase in the psiCHECK2 vector (Fig. 5A). The miR-
27-binding sites are perfectly complementary to miR-27 but
contain an internal loop at nucleotides 9–12 to prevent endo-
nucleolytic cleavage, as described in Ref. 29. The miR-27 sensor
displayed an approximately twofold reduction in the ratio of
Renilla/Fireﬂy expression compared with the control psiCHECK2
vector, consistent with regulation by endogenous miR-27 (Fig.
5A). miR-27-dependent repression of the Renilla luciferase was
enhanced by cotransfection with a synthetic miR-27 mimic
(resulting in an approximately ﬁvefold reduction in the Renilla/
Fireﬂy ratio). In contrast, cotransfection of a synthetic miR-27
inhibitor relieved the repression, Fig. 5A. Cotransfection of the
sensor with a plasmid encoding m169 produced the same result
as the synthetic miR-27 inhibitor, relieving the repression of
Renilla luciferase with no effects on the control psiCHECK2
vector. Mutation of nucleotides in m169 that interact with
positions 1–3 in miR-27 eliminated this effect (Fig. 5A). To di-
rectly examine the impact of m169 on miR-27 during infection,
we measured miR-27 levels in cells in which m169 RNA was
depleted by a custom pool of 3 siRNAs targeting the viral
transcript. Transfection with the m169 siRNAs resulted in >95%
knockdown of m169 and resulted in 80% relief of miR-27 down-
regulation at 24 h postinfection (Fig. 5B). Transfection of RISC-
free siRNA (a small RNA duplex that is taken up by cells but is
chemically modiﬁed to prevent incorporation into RISC) or an
siRNA targeting GAPDH had no effect on miR-27 levels in
uninfected or infected cells (Fig. 5B and Fig. S4). We, therefore,
conclude that the rescue of miR-27 levels in these experiments is
not attributable to nonspeciﬁc effects of transfection or satura-
tion of the RISC machinery by the siRNAs. The speciﬁcity of
m169 function was conﬁrmed by comparison with two other host
miRNAs: miR-16, a miRNA that does not change in expression
level in response to infection and miR-199a-3p, another miRNA
that is down-regulated during infection (14). Neither miRNA
displayed a signiﬁcant change in expression level as a result of
m169 knockdown (Fig. 5B), supporting the conclusion that the
m169 RNA speciﬁcally targets miR-27, rather than globally
inhibiting the host miRNA machinery. To conﬁrm that miR-27
degradation requires base pair interactions with m169, we in-
troduced 11 mutations into the miRNA-binding site in the viral
genome. The mutations eliminate pairing to miR-27 and in-
troduce complementarity to another cellular miRNA, miR-24.
miR-24 is derived from the same primary transcript as miR-27
and also displays antiviral properties against MCMV (14) but
does not change in expression level during the lytic infection
(16). As shown in Fig. 5C, substitution of 11 nt in m169 abolished
virus-induced degradation of miR-27 and resulted in a gain-of-
function ability of MCMV to down-regulate miR-24.
m169 RNA Is Unrelated to the Other Known miR-27 Inhibitor, HSUR-1,
and Localizes to the Cytoplasm. The only other known miRNA
inhibitor that has been described in a mammalian system is
HSUR-1, a snRNA that mediates miR-27 degradation in HVS-
transformed T cells (17). A comparison of HSUR-1 and m169
sequences shows identical sequence at the site of base-pairing to
nucleotides 2–7 and 16–19 in miR-27. However, the length of the
central bulge and extent of 3′ pairing to miR-27 differs in these
Table 1. Top Ago2-binding sites in the MCMV transcriptome
Rank Start End Genome strand Cluster hit density Annotation
1 811 835 − 1,020 miR-m01-2
2 433 457 − 462 miR-m01-4
3 23,665 23,689 − 237 miR-M23-1–3p
4 131,353 131,377 + 169 miR-m88-1
5 228,044 228,068 − 146 3′ UTR of predicted m169
6 23,468 23,492 − 130 miR-M23-2
7 2,008 2,032 − 95 Unannotated miR-m01-1*
8 574 598 − 85 miR-m01-3*
9 395 419 − 81 miR-m01-4*
10 767 791 − 59 miR-m01-2*
deletions 
miR-27 seed site
228,120 genome position 228,080 228,040 228,000
5’GACGAUCUGCGGAAUAAUAAGCUGUGAAAAGAAGTC 3’
3’CGCCUUG UGACACUU 5’GAAUCG
. .
miR-27a
4%
0
169 UTR
Fig. 3. Site of Ago2 crosslinking to the m169 transcript. Distribution of
Solexa reads (blue) downstream of the m169 ORF (Upper) and complemen-
tarity between the viral RNA sequence and miR-27 (Lower). Location of
deletions identiﬁed in Solexa reads are shown in red on a scale depicting
percentage deletions at each location; the miR-27 seed site is shown in green.
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two RNAs: HSUR-1 is complementary to eight consecutive
nucleotides in the 3′ end of miR-27 with a 3-nt central bulge,
whereas m169 is complementary to six consecutive nucleotides in
the 3′ end with a 5-nt central bulge ﬂanked by G-U wobble pairs
(Fig. 6A). These RNAs differ signiﬁcantly in length (143 nt
versus 1,669 nt) and, apart from the miR-27-binding site, do not
display obvious homology in primary sequence or predicted
folding around the miR-27-binding site. Because m169 and
HSUR-1 are unlikely to derive from a common ancestor, their
roles in mediating miR-27 degradation may represent conver-
gent evolution. The mechanism of miR-27 degradation induced
by HSUR-1 is not yet known, but HSUR-1, like other snRNAs,
associates with Sm proteins and localizes to the nucleus (30).
There are also reports that some cellular miRNAs display nuclear
localization (31, 32). To examine localization of m169 and miR-
27, we carried out in situ hybridizations with digoxigenin (DIG)-
labeled probes directed against these RNAs in uninfected and
infected cells. As shown in Fig. 6B, the miR-27 signal in unin-
fected cells appears in the cytoplasm and displays a clear re-
duction in intensity at 16 h postinfection. A probe against miR-16
demonstrates that this miRNA also localizes to the cytoplasm
but shows no loss of signal upon infection (Fig. 6B). A probe
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Fig. 4. m169 is a 1,669-nt transcript with expression kinetics that correlate
with the degradation of miR-27. (A) Schematic of m169 gene locus based on
5′ and 3′ RACE. (B) Left, validation of m169 transcriptional start site based on
primer extension using a 20-nt primer starting at position 229,039. (B) Center,
PCR product of the m169 transcript using a forward primer at the transcrip-
tional start site and reverse primer at the 3′ end; the cDNA was created with
an oligo(dT) primer. (B) Right, Northern blot analysis with a 80-nt probe that
spans the miR-27-binding site in m169. RNA was collected from NIH 3T3 cells
mock-infected (−) or infected with MCMV at MOI = 5 (+) for 48 h and then
resolved on a formaldehyde-agarose gel. (C) Left, Northern blot analysis with
RNA collected fromNIH 3T3 cells mock infected (−) or infected (+) withMCMV
(MOI = 5) for the indicated times. (C) Right, Northern blot analysis with RNA
collected from NIH 3T3 cells mock-infected or infected with MCMV (MOI = 5)
for 16 h in the absence and presence of 5 μg/mL actinomycin D (ACT); 5 μg of
total RNA was loaded per lane. (D) Absolute quantiﬁcation of m169 and miR-
27 at the indicated time points postinfection (MOI = 5) based on qRT-PCR,
using synthetic miR-27 and in vitro transcribed m169 as standards.
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sensor contains three miR-27-binding sites spaced 11-nt apart in the 3′UTR of
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m169 mutant plasmid are noted in bold. (B) Northern blot analysis following
transfection of NIH 3T3 cells with 25 nM m169 siRNA pool or RISC-free control
siRNA beforemock infection (“uninfected”) or infectionwithMCMVatMOI = 5
for 24 h. (C, Upper) Northern blot analysis of NIH 3T3 cells mock-infected or
infected with the wild-type virus or themutant virus (MCMV-24mut) atMOI = 5
for 24 h. (C, Lower) Schematic of the mutations in m169 (bold) that introduce
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against m169 RNA revealed it also to be localized within the
cytoplasm in infected cells, and no signal was observed using
a probe against the antisense sequence of m169 (Fig. 6B). We,
therefore, conclude that m169 RNA and miR-27 predominantly
localize to the cytoplasm in these cells.
Discussion
The interpretation of miRNA-binding sites within animal and viral
genomes has generally been based on the expectation that miRNAs
exert a negative regulatory function on the genes with which they
interact. The ﬁndings presented here suggest that the opposite can
also occur, with the “target”mRNAactively regulating themiRNA.
Speciﬁcally, we demonstrate that MCMV encodes a miRNA in-
hibitor that is responsible for the robust down-regulation of miR-27
observed during the lytic infection (16). We further show that the
miR-27 inhibitor is capped, polyadenylated, and expressed in the
cytoplasm at a comparable level to miR-27 between 12 and 24 h
postinfection (Figs. 4 and 6B). Hundreds of potential miR-27 in-
teraction sites are predicted in the MCMV transcriptome. How-
ever, these analyses demonstrate that m169 is the only inhibitor
responsible for the degradation of miR-27 upon infection. This
underscores the importance of biochemical approaches for identi-
fying functional miRNA-binding sites in viruses.
Only one other miRNA inhibitor has been identiﬁed to date in
a viral system: HSUR-1, the snRNA encoded by HVS, which does
not share obvious features in common with m169, beyond the miR-
27-binding site. HVS is a γ-herpesvirus that infects New World
primates and is separated from MCMV by hundreds of millions of
years of evolution (33). The existence of a miR-27 inhibitor in
MCMV suggests that this class of molecule might be a more com-
mon feature in viral genomes and illuminates the potential diversity
of RNAs that can mediate miRNA degradation. Our results also
suggest that miRNA inhibitors might readily be mistaken for tar-
gets, becausem169 appears strikingly similar to a “normal” targeted
mRNA. Speciﬁcally, the miRNA-binding site is in the 3′UTR of an
annotated ORF and the miR-27–m169 binding interaction involves
seed pairing, a predominant recognition criteria for bona ﬁde tar-
gets of miRNAs (34). It is, therefore, possible that other “killer
targets” exist that have not been annotated as such.
RNA–RNA recognition is the central means by which small
guide RNAs, including miRNAs, mediate speciﬁcity in interactions
between ribonucleoprotein complexes. Our ﬁndings support the
idea that this principle extends to regulation of the guide RNAs
themselves, enabling speciﬁc miRNAs to be regulated without
global effects on themiRNAome. This concept was ﬁrst introduced
in the context of “miRNA sponges,” a term coined for transgenes
containing multiple miRNA-binding sites that act as competitive
inhibitors of a miRNA (35). In several cases, sponges, or related
constructs, have also been shown to cause a reduction in the level of
the endogenous miRNA (36, 37). Ameres et al. (38) recently
showed that extensive complementarity between a miRNA and an
artiﬁcial target can induce miRNA degradation in ﬂies, which was
also observed in HeLa cells. This degradation was attributed to the
3′ end pairing and subsequent trimming of themiRNAs, whichmay
relate to the observations with sponges, reviewed in Ref. 39. The
m169–miR-27 binding interaction does not appear to ﬁt the
miRNA degradation model of Ameres et al. (38), because of the
length of the central bulge. However, further work is required to
deﬁne the criteria that determine whether a miRNA interaction
partner is a target, sponge, or other type of inhibitor. This is likely
to relate to the concentration of the interaction partner in relation
to the miRNA, the pattern and extent of pairing between the two
RNAs (beyond seed site recognition), and, potentially, the pres-
ence of motifs in the interaction partner involved in recruiting
factors involved in degradation. At present, it is unclear why only
miR-27 is targeted by MCMV. This miRNA is derived from a pri-
mary transcript that also encodes miR-23 and miR-24. All three
miRNAs in this cluster target genes associated with cell pro-
liferation, differentiation, and cancer and are predicted to function
in a cooperative fashion (40). miR-24, in addition to miR-27, dis-
plays antiviral properties when overexpressed (14), and we show
that the virus can be engineered to target miR-24 by mutation of 11
nt in the miRNA-binding site (Fig. 5C). Our ﬁndings suggest that
viruses may have the capacity to target various cellular miRNAs.
Further analyses will shed light on why two diverse herpesviruses
have devoted genome space to speciﬁcally inhibiting miR-27.
Materials and Methods
For a full description of all methods used here, see SI Materials and Methods.
All oligonucleotides used in these studies are listed in Table S4. The tagged
mouse Ago2 was constructed by ligating the PTH tag sequence (ampliﬁed
from the pRS415 plasmid containing the ProtA-TEV-His6-MCS construct, a
generous gift from the laboratory of Markus T. Bohnsack, Institut für Mole-
kulare Biowissenschaften, Goethe Universität Frankfurt, Frankfurt, Germany)
to the N terminus of mouse Ago2, which was then cloned into the pCDNA3
vector. NIH 3T3 cells (1.2 × 107 cells per sample, distributed in four 15-cm
dishes) were transfected with 60 μg of pcDNA3-PTH-Ago2 plasmid in 0.3%
Lipofectamine 2000 (Invitrogen) and 20 h posttransfection infected with
MCMV (Smith strain) at an MOI of 5. At 8 h postinfection, cells were washed
with PBS, immediately UV-irradiated at 254 nm (400 mJ/cm2; Uvitec), and the
CRAC pull-down technique was performed as described previously (19), with
modiﬁcations detailed in SI Materials and Methods. For construction of the
miR-27 sensor, three miR-27-binding sites spaced 11 nt apart were cloned
behind the 3′UTR of Renilla luciferase in the psiCHECK2 vector (Promega) as
in Ref. 29. Knockdown of m169 was carried out by transfecting a pool of
custom siRNAs into NIH 3T3 cells at a ﬁnal concentration of 25 nM in 0.3%
DharmaFECT 1 (Thermoﬁsher) 24 h before infection. MCMVwas derived from
the pSM3fr BAC (41). The MCMV-24 mutant was constructed using the
adapted protocol described in Ref. 42, with modiﬁcations described in SI
Materials and Methods. For in situ hybridization analyses, LNA-incorporated
miRNA probes were purchased from Exiqon and the m169 probe and anti-
sense control probe were generated using the DIG RNA labeling kit (Roche).
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Fig. 6. Sequence alignment of miR-27-binding sites in HSUR-1 and m169
and cytoplasmic localization of miR-27 and m169 in NIH 3T3 cells. (A) Com-
plementarity of m169 and HSUR-1 to miR-27; green box indicates the seed
site. (B) In situ detection of DIG-labeled probes against miR-27, miR-16,
m169, and antisense m169 in NIH 3T3 cells, uninfected or at 16 h post-
infection. DIG-labeled probes were detected by FITC-tyramide ampliﬁcation
(green) and overlaid on nuclear DAPI signal (blue). Images are representative
of three independent experiments.
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